Intranasal breast milk

Phase 1Biologic

SSemmelweis University

Intranasal breast milk is one of 6 biologic programs targeting Breast. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BreastRecruiting

BreastPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Breast

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

1 2

Lynparza

AstraZeneca

Phase 2

1 3

Prolia

OOrganon and Co

Phase 2

1 4

Calcium

Eli Lilly

Phase 2

1 5

Spectracef

Jazz Pharmaceuticals

Preclinical

1 6

Intranasal breast milk

SSemmelweis University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1Recruiting

Breast

NCT06747260

Q4 2030

Phase 1Recruiting

Breast

NCT06746532

Clinical

Trials by Indication[1]

Breast2 trials

Feasibility and Safety of Intranasally Administered Breast Milk in HIE

Recruiting·SSemmelweis University·Phase 1·NCT06747260·10 enrolled

Intranasal Breast Milk Therapy in HIE

Recruiting·SSemmelweis University·Phase 1·NCT06746532·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intranasal breast milk. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal breast milk compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal breast milk. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Semmelweis University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSemmelweis University

Intranasal breast milk

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q4 2030

Trials by Indication[1]

Breast2 trials

References

Drug Info

Quick Facts

Related News